Dicer converts double-stranded RNA into short interfering RNAs, creating the small-RNA signals needed for targeting. One strand then loads into the RNA-induced silencing complex, or RISC. This assembly connects RNA processing with gene regulation because the retained guide strand provides the sequence information used to recognize a matching messenger RNA.
The guide strand directs RISC toward messenger RNA containing a complementary sequence. This sequence recognition gives RNAi its specificity, allowing regulation of a particular gene transcript rather than producing a general reduction in protein production. Once the target is recognized, Argonaute can promote messenger RNA cleavage or contribute to translational repression.
Targeted silencing can occur through more than one downstream effect. In the canonical pathway, Argonaute may cleave a complementary messenger RNA, reducing the transcript available for protein production. Alternatively, the matched transcript may undergo translational repression, which limits protein synthesis without the same cleavage outcome. These mechanisms provide distinct routes to reduced gene expression.
Researchers use RNAi to reduce production of a selected protein and then examine the resulting biological effects. This creates a targeted loss-of-function approach, linking a gene or its protein product to a cellular or organismal process. Comparing silenced conditions with appropriate nonsilenced conditions can help reveal the function of endogenous genes.
Reducing expression of a selected gene or protein allows investigators to examine how that factor contributes to a disease pathway. The resulting changes can help identify relationships between gene activity and disease-related processes. Because the mechanism is sequence-specific, RNAi supports focused interrogation of particular molecular targets rather than relying only on broad changes in gene expression.
RNAi provides a model for deliberately lowering production of specific proteins through sequence-guided silencing. This principle is relevant to therapeutic research because disease-associated pathways may depend on particular gene products whose reduction could alter the pathway. The same mechanism also reflects biological defenses against some foreign genetic material, connecting basic biology with treatment development.